-
Proteostasis Therapeutics Shares Surge On Positive Preliminary Cystic Fibrosis Trial Results
Thursday, October 18, 2018 - 11:15am | 384Read More...Biotech Proteostasis Therapeutics Inc. (NASDAQ: PTI) develops therapeutics for the treatment of cystic fibrosis and associated disorders. The company’s lead product candidates are PTI-801 and PTI-808. What Happened Proteostasis shares were surging 300 percent on the announcement of positive...
-
3 Reasons To Like Vertex Pharma Shares
Friday, September 29, 2017 - 8:56am | 401Read More...Analysts at BTIG laid out the bullish case for owning shares of Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) — a "storied" company with a strong growth outlook. BTIG's Dane Leone initiates coverage of Vertex's stock with a Buy and $200 price target, on the thesis that...
-
More Than 30% Upside Seen For Vertex Stock On The Heels Of Phase 2 Data
Wednesday, July 19, 2017 - 9:45am | 348Read More...Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX)'s stock soared 25 percent after the company reported encouraging phase 2 data. The company's three-drug cocktails showed an improvement in lung function among patients with cystic fibrosis by 9.6 percentage points or more, which was better...
-
Corbus Pharma's Positive Phase 2 Study: Safety First
Thursday, March 30, 2017 - 2:56pm | 358Read More...Corbus Pharmaceuticals Holdings Inc (NASDAQ: CRBP) has received a price target increase to $24 from $17 from Cantor Fitzgerald, which reiterated an Overweight rating following positive data from the company’s Phase 2 study in Cystic Fibrosis. “Treatment with anabasum at the highest dose...
-
Here's Why Shares Of Vertex Pharmaceuticals Tumbled
Friday, February 5, 2016 - 3:09pm | 224Read More...Shares of Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) tumbled by more than 6 percent on Friday after the company confirmed it has received a letter from the U.S. Food and Drug Administration for use of Kalydeco in people with cystic fibrosis. Vertex Pharmaceuticals said that it received...
-
Goldman Comments On Vertex Pharmaceuticals Following FDA Approval
Thursday, July 2, 2015 - 1:41pm | 242Read More...Shares of Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) were trading higher by nearly 4 percent on Thursday after the FDA approved the company's Orkambi (lumacafor/ivacaftor) for the treatment of cystic fibrosis patients 12 years and older. Commenting on the FDA's approval, Terence Flynn, PhD...
